{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:22:15Z","timestamp":1785799335113,"version":"3.56.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100017691","name":"Guangxi Key Research and Development Program","doi-asserted-by":"publisher","award":["GuikeAB21196022"],"award-info":[{"award-number":["GuikeAB21196022"]}],"id":[{"id":"10.13039\/501100017691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013091","name":"Science and Technology Major Project of Guangxi","doi-asserted-by":"publisher","award":["GuikeAA22096032"],"award-info":[{"award-number":["GuikeAA22096032"]}],"id":[{"id":"10.13039\/501100013091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270806"],"award-info":[{"award-number":["82270806"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Major Project of Guangxi Innovation Driven","award":["AA18118016"],"award-info":[{"award-number":["AA18118016"]}]},{"name":"Guangxi Key Laboratory for Genomic and Personalized Medicine","award":["22-35-17"],"award-info":[{"award-number":["22-35-17"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04593-9","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:12:18Z","timestamp":1775095938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aldosterone fuels the progression of cardiovascular-kidney -metabolic syndrome: focus on primary aldosteronism spectrum"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6814-2943","authenticated-orcid":false,"given":"Huannan","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9584-5898","authenticated-orcid":false,"given":"Xinyang","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-0236","authenticated-orcid":false,"given":"Mingli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0956-5097","authenticated-orcid":false,"given":"Shengzhu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9721-8086","authenticated-orcid":false,"given":"Jianling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3047-3138","authenticated-orcid":false,"given":"Zengnan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"4593_CR1","doi-asserted-by":"publisher","unstructured":"C.E. Ndumele, J. Rangaswami, S.L. Chow, I.J. Neeland, K.R. Tuttle, S.S. Khan et al., Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 148(20), 1606\u2009\u2013\u200935. (2023) https:\/\/doi.org\/10.1161\/cir.0000000000001184","DOI":"10.1161\/cir.0000000000001184"},{"issue":"20","key":"4593_CR2","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/cir.0000000000001186","volume":"148","author":"C.E. Ndumele","year":"2023","unstructured":"C.E. Ndumele, I.J. Neeland, K.R. Tuttle, S.L. Chow, R.O. Mathew, S.S. Khan et al., A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation. 148(20), 1636\u20131664 (2023). https:\/\/doi.org\/10.1161\/cir.0000000000001186","journal-title":"Circulation"},{"issue":"9","key":"4593_CR3","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1161\/hypertensionaha.122.17964","volume":"79","author":"F. Buffolo","year":"2022","unstructured":"F. Buffolo, M. Tetti, P. Mulatero, S. Monticone, Aldosterone as a Mediator of Cardiovascular Damage. Hypertension. 79(9), 1899\u20131911 (2022). https:\/\/doi.org\/10.1161\/hypertensionaha.122.17964","journal-title":"Hypertension"},{"issue":"24","key":"4593_CR4","doi-asserted-by":"publisher","first-page":"e023082","DOI":"10.1161\/jaha.121.023082","volume":"10","author":"J. Hu","year":"2021","unstructured":"J. Hu, H. Shen, P. Huo, J. Yang, P.J. Fuller, K. Wang et al., Heightened Cardiovascular Risk in Hypertension Associated With Renin-Independent Aldosteronism Versus Renin-Dependent Aldosteronism: A Collaborative Study. J. Am. Heart Assoc. 10(24), e023082 (2021). https:\/\/doi.org\/10.1161\/jaha.121.023082","journal-title":"J. Am. Heart Assoc."},{"issue":"3","key":"4593_CR5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/hypertensionaha.118.11065","volume":"72","author":"G. Jia","year":"2018","unstructured":"G. Jia, A.R. Aroor, M.A. Hill, J.R. Sowers, Role of Renin-Angiotensin-Aldosterone System Activation in Promoting Cardiovascular Fibrosis and Stiffness. Hypertension. 72(3), 537\u2013548 (2018). https:\/\/doi.org\/10.1161\/hypertensionaha.118.11065","journal-title":"Hypertension"},{"issue":"11","key":"4593_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41574-022-00730-2","volume":"18","author":"A.F. Turcu","year":"2022","unstructured":"A.F. Turcu, J. Yang, A. Vaidya, Primary aldosteronism - a multidimensional syndrome. Nat. Rev. Endocrinol. 18(11), 665\u2013682 (2022). https:\/\/doi.org\/10.1038\/s41574-022-00730-2","journal-title":"Nat. Rev. Endocrinol."},{"issue":"9","key":"4593_CR7","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","volume":"110","author":"G.K. Adler","year":"2025","unstructured":"G.K. Adler, M. Stowasser, R.R. Correa, N. Khan, G. Kline, M.J. McGowan et al., Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 110(9), 2453\u20132495 (2025). https:\/\/doi.org\/10.1210\/clinem\/dgaf284","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"4593_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.7326\/m17-0882","volume":"167","author":"J.M. Brown","year":"2017","unstructured":"J.M. Brown, C. Robinson-Cohen, M.A. Luque-Fernandez, M.A. Allison, R. Baudrand, J.H. Ix et al., The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study. Ann. Intern. Med. 167(9), 630\u2013641 (2017). https:\/\/doi.org\/10.7326\/m17-0882","journal-title":"Ann. Intern. Med."},{"issue":"13","key":"4593_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1161\/circulationaha.124.073507","volume":"152","author":"R. Goupil","year":"2025","unstructured":"R. Goupil, L.C. Desbiens, A. Merabtine, M. Agharazii, F. Madore, A. Vaidya et al., Subclinical Primary Aldosteronism and Major Adverse Cardiovascular Events: A Longitudinal Population-Based Cohort Study. Circulation. 152(13), 913\u2013923 (2025). https:\/\/doi.org\/10.1161\/circulationaha.124.073507","journal-title":"Circulation"},{"issue":"12","key":"4593_CR10","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/ajh\/hpac079","volume":"35","author":"A. Vaidya","year":"2022","unstructured":"A. Vaidya, G.L. Hundemer, K. Nanba, W.W. Parksook, J.M. Brown, Primary Aldosteronism: State-of-the-Art Review. Am. J. Hypertens. 35(12), 967\u2013988 (2022). https:\/\/doi.org\/10.1093\/ajh\/hpac079","journal-title":"Am. J. Hypertens."},{"issue":"7","key":"4593_CR11","doi-asserted-by":"publisher","first-page":"e030142","DOI":"10.1161\/jaha.123.030142","volume":"13","author":"J.M. Brown","year":"2024","unstructured":"J.M. Brown, Adverse Effects of Aldosterone: Beyond Blood Pressure. J. Am. Heart Assoc. 13(7), e030142 (2024). https:\/\/doi.org\/10.1161\/jaha.123.030142","journal-title":"J. Am. Heart Assoc."},{"issue":"6","key":"4593_CR12","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1210\/endrev\/bnaa008","volume":"41","author":"M. Sherlock","year":"2020","unstructured":"M. Sherlock, A. Scarsbrook, A. Abbas, S. Fraser, P. Limumpornpetch, R. Dineen et al., Adrenal Incidentaloma Endocr. Rev. 41(6), 775\u2013820 (2020). https:\/\/doi.org\/10.1210\/endrev\/bnaa008","journal-title":"Adrenal Incidentaloma Endocr. Rev."},{"issue":"4","key":"4593_CR13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1152\/physrev.00026.2015","volume":"96","author":"M. Stowasser","year":"2016","unstructured":"M. Stowasser, R.D. Gordon, Primary Aldosteronism: Changing Definitions and New Concepts of Physiology and Pathophysiology Both Inside and Outside the Kidney. Physiol. Rev. 96(4), 1327\u20131384 (2016). https:\/\/doi.org\/10.1152\/physrev.00026.2015","journal-title":"Physiol. Rev."},{"issue":"6","key":"4593_CR14","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.2215\/cjn.08580813","volume":"10","author":"B.F. Palmer","year":"2015","unstructured":"B.F. Palmer, Regulation of Potassium Homeostasis. Clin. J. Am. Soc. Nephrol. 10(6), 1050\u20131060 (2015). https:\/\/doi.org\/10.2215\/cjn.08580813","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"6","key":"4593_CR15","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1210\/er.2018-00139","volume":"39","author":"A. Vaidya","year":"2018","unstructured":"A. Vaidya, P. Mulatero, R. Baudrand, G.K. Adler, The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment. Endocr. Rev. 39(6), 1057\u20131088 (2018)","journal-title":"Endocr. Rev."},{"issue":"1","key":"4593_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-44-1-1","volume":"44","author":"J.W. Conn","year":"1956","unstructured":"J.W. Conn, L.H. Louis, Primary aldosteronism, a new clinical entity. Ann. Intern. Med. 44(1), 1\u201315 (1956). https:\/\/doi.org\/10.7326\/0003-4819-44-1-1","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"4593_CR17","first-page":"3","volume":"45","author":"JW Conn","year":"1955","unstructured":"J.W. Conn, Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J. Lab. Clin. Med. 45(1), 3\u201317 (1955)","journal-title":"J. Lab. Clin. Med."},{"issue":"5","key":"4593_CR18","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1161\/hypertensionaha.116.08952","volume":"69","author":"R. Baudrand","year":"2017","unstructured":"R. Baudrand, F.J. Guarda, C. Fardella, G. Hundemer, J. Brown, G. Williams et al., Continuum of Renin-Independent Aldosteronism in Normotension. Hypertension. 69(5), 950\u2013956 (2017). https:\/\/doi.org\/10.1161\/hypertensionaha.116.08952","journal-title":"Hypertension"},{"key":"4593_CR19","doi-asserted-by":"crossref","unstructured":"J.M. Brown, M. Siddiqui, D.A. Calhoun, R.M. Carey, P.N. Hopkins, G.H. Williams et al., The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann Intern Med. 173(1) 2020 https:\/\/doi.org\/10-20.10.7326\/m20-0065","DOI":"10.7326\/M20-0065"},{"issue":"2","key":"4593_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1161\/hypertensionaha.124.24153","volume":"82","author":"J.M. Brown","year":"2025","unstructured":"J.M. Brown, B. Honzel, L.C. Tsai, J. Milks, Y.M. Neibuhr, A.J. Newman et al., Characterizing Origins Prim. Aldosteronism Hypertens. 82(2), 306\u2013318 (2025). https:\/\/doi.org\/10.1161\/hypertensionaha.124.24153","journal-title":"Characterizing Origins Prim. Aldosteronism Hypertens."},{"issue":"5","key":"4593_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11906-022-01176-7","volume":"24","author":"T. Wannachalee","year":"2022","unstructured":"T. Wannachalee, L. Lieberman, A.F. Turcu, High Prevalence of Autonomous Aldosterone Production in Hypertension: How to Identify and Treat It. Curr Hypertens Rep. 24(5), 123\u2009\u2013\u200932. (2022) https:\/\/doi.org\/10.1007\/s11906-022-01176-7","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"4593_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1210\/clinem\/dgaa484","volume":"106","author":"T.A. Williams","year":"2021","unstructured":"T.A. Williams, C.E. Gomez-Sanchez, W.E. Rainey, T.J. Giordano, A.K. Lam, A. Marker et al., International Histopathology Consensus for Unilateral Primary Aldosteronism. J. Clin. Endocrinol. Metab. 106(1), 42\u201354 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgaa484","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4593_CR23","doi-asserted-by":"crossref","unstructured":"K. Omata, S.K. Anand, D.H. Hovelson, C.J. Liu, Y. Yamazaki, Y. Nakamura et al., Aldosterone-Producing Cell Clusters Frequently Harbor Somatic Mutations and Accumulate With Age in Normal Adrenals. J. Endocr. Soc. 1(7), 787\u2013799 (2017).","DOI":"10.1210\/js.2017-00134"},{"issue":"4","key":"4593_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1161\/circulationaha.117.028201","volume":"136","author":"K. Nanba","year":"2017","unstructured":"K. Nanba, A. Vaidya, G.H. Williams, I. Zheng, T. Else, W.E. Rainey, Age-Related Auton. Aldosteronism Circulation. 136(4), 347\u2013355 (2017). https:\/\/doi.org\/10.1161\/circulationaha.117.028201","journal-title":"Age-Related Auton. Aldosteronism Circulation"},{"issue":"1","key":"4593_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1210\/endrev\/bnad024","volume":"45","author":"G.L. Hundemer","year":"2024","unstructured":"G.L. Hundemer, A.A. Leung, G.A. Kline, J.M. Brown, A.F. Turcu, A. Vaidya, Biomarkers to Guide Medical Therapy in Primary Aldosteronism. Endocr. Rev. 45(1), 69\u201394 (2024). https:\/\/doi.org\/10.1210\/endrev\/bnad024","journal-title":"Endocr. Rev."},{"issue":"24","key":"4593_CR26","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/cir.0000000000001191","volume":"148","author":"S.S. Khan","year":"2023","unstructured":"S.S. Khan, J. Coresh, M.J. Pencina, C.E. Ndumele, J. Rangaswami, S.L. Chow et al., Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. Circulation. 148(24), 1982\u20132004 (2023). https:\/\/doi.org\/10.1161\/cir.0000000000001191","journal-title":"Circulation"},{"issue":"18","key":"4593_CR27","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.jacc.2024.03.368","volume":"83","author":"A.M.K. Minhas","year":"2024","unstructured":"A.M.K. Minhas, R.O. Mathew, L.S. Sperling, V. Nambi, S.S. Virani, S.D. Navaneethan et al., Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome in the United States. J. Am. Coll. Cardiol. 83(18), 1824\u20131826 (2024). https:\/\/doi.org\/10.1016\/j.jacc.2024.03.368","journal-title":"J. Am. Coll. Cardiol."},{"issue":"21","key":"4593_CR28","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1001\/jama.2024.6892","volume":"331","author":"R. Aggarwal","year":"2024","unstructured":"R. Aggarwal, J.W. Ostrominski, M. Vaduganathan, Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011\u20132020. Jama. 331(21), 1858\u20131860 (2024). https:\/\/doi.org\/10.1001\/jama.2024.6892","journal-title":"Jama"},{"key":"4593_CR29","doi-asserted-by":"publisher","unstructured":"S.E. Claudel, I.M. Schmidt, S.S. Waikar, A. Verma, Cumulative Incidence of Mortality Associated with Cardiovascular-Kidney-Metabolic Syndrome. J Am Soc Nephrol. 2025. https:\/\/doi.org\/10.1681\/asn.0000000637","DOI":"10.1681\/asn.0000000637"},{"issue":"3","key":"4593_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2025.05.030","volume":"86","author":"D. He","year":"2025","unstructured":"D. He, X. Zhang, C. Li, C. Yang, M. Yu, J. Wang et al., Rising Prevalence of Cardiovascular-Kidney-Metabolic Syndrome in China, 2010\u20132019: National Cross-Sectional Surveys. J. Am. Coll. Cardiol. 86(3), 213\u2013216 (2025). https:\/\/doi.org\/10.1016\/j.jacc.2025.05.030","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"4593_CR31","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1161\/hypertensionaha.116.07806","volume":"68","author":"T. Dudenbostel","year":"2016","unstructured":"T. Dudenbostel, L. Ghazi, M. Liu, P. Li, S. Oparil, D.A. Calhoun, Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension. Hypertension. 68(4), 995\u20131003 (2016). https:\/\/doi.org\/10.1161\/hypertensionaha.116.07806","journal-title":"Hypertension"},{"issue":"5","key":"4593_CR32","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/ajh\/hpz023","volume":"32","author":"A. Vecchiola","year":"2019","unstructured":"A. Vecchiola, C.A. Fuentes, E.R. Barros, A. Mart\u00ednez-Aguayo, H. Garc\u00eda, F. Allende et al., The Aldosterone\/Renin Ratio Predicts Cardiometabolic Disorders in Subjects Without Classic Primary Aldosteronism. Am. J. Hypertens. 32(5), 468\u2013475 (2019). https:\/\/doi.org\/10.1093\/ajh\/hpz023","journal-title":"Am. J. Hypertens."},{"issue":"24","key":"4593_CR33","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1161\/circulationaha.120.050896","volume":"143","author":"J.J. Joseph","year":"2021","unstructured":"J.J. Joseph, N.K. Pohlman, S. Zhao, D. Kline, G. Brock, J.B. Echouffo-Tcheugui et al., Association of Serum Aldosterone and Plasma Renin Activity With Ambulatory Blood Pressure in African Americans: The Jackson Heart Study. Circulation. 143(24), 2355\u20132366 (2021). https:\/\/doi.org\/10.1161\/circulationaha.120.050896","journal-title":"Circulation"},{"issue":"2","key":"4593_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/circulationaha.123.066389","volume":"149","author":"G.L. Hundemer","year":"2024","unstructured":"G.L. Hundemer, M. Agharazii, F. Madore, A. Vaidya, J.M. Brown, A.A. Leung et al., Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study. Circulation. 149(2), 124\u2013134 (2024). https:\/\/doi.org\/10.1161\/circulationaha.123.066389","journal-title":"Circulation"},{"issue":"8","key":"4593_CR35","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1097\/HJH.0b013e328354f65b","volume":"30","author":"S. Terata","year":"2012","unstructured":"S. Terata, M. Kikuya, M. Satoh, T. Ohkubo, T. Hashimoto, A. Hara et al., Plasma renin activity and the aldosterone-to-renin ratio are associated with the development of chronic kidney disease: the Ohasama Study. J. Hypertens. 30(8), 1632\u20131638 (2012). https:\/\/doi.org\/10.1097\/HJH.0b013e328354f65b","journal-title":"J. Hypertens."},{"issue":"38","key":"4593_CR36","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","volume":"43","author":"A. Verma","year":"2022","unstructured":"A. Verma, A. Vaidya, S. Subudhi, S.S. Waikar, Aldosterone in chronic kidney disease and renal outcomes. Eur. Heart J. 43(38), 3781\u20133791 (2022). https:\/\/doi.org\/10.1093\/eurheartj\/ehac352","journal-title":"Eur. Heart J."},{"issue":"1","key":"4593_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1161\/hypertensionaha.120.15006","volume":"76","author":"K. Inoue","year":"2020","unstructured":"K. Inoue, D. Goldwater, M. Allison, T. Seeman, B.R. Kestenbaum, K.E. Watson, Serum Aldosterone Concentration, Blood Pressure, and Coronary Artery Calcium: The Multi-Ethnic Study of Atherosclerosis. Hypertension. 76(1), 113\u2013120 (2020). https:\/\/doi.org\/10.1161\/hypertensionaha.120.15006","journal-title":"Hypertension"},{"issue":"1","key":"4593_CR38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12902-020-00654-w","volume":"20","author":"W. Manosroi","year":"2020","unstructured":"W. Manosroi, P. Atthakomol, High body fat percentage is associated with primary aldosteronism: a cross-sectional study. BMC Endocr. Disord. 20(1), 175 (2020). https:\/\/doi.org\/10.1186\/s12902-020-00654-w","journal-title":"BMC Endocr. Disord"},{"issue":"14","key":"4593_CR39","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S. Monticone","year":"2017","unstructured":"S. Monticone, J. Burrello, D. Tizzani, C. Bertello, A. Viola, F. Buffolo et al., Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J. Am. Coll. Cardiol. 69(14), 1811\u20131820 (2017). https:\/\/doi.org\/10.1016\/j.jacc.2017.01.052","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"4593_CR40","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s12020-021-02704-2","volume":"73","author":"M. Fern\u00e1ndez-Arg\u00fceso","year":"2021","unstructured":"M. Fern\u00e1ndez-Arg\u00fceso, E. Pascual-Corrales, N. Bengoa Rojano, A. Garc\u00eda Cano, L. Jim\u00e9nez Mendiguch\u00eda, M. Araujo-Castro, Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study. Endocrine. 73(2), 439\u2013446 (2021). https:\/\/doi.org\/10.1007\/s12020-021-02704-2","journal-title":"Endocrine"},{"key":"4593_CR41","doi-asserted-by":"publisher","first-page":"155593","DOI":"10.1016\/j.metabol.2023.155593","volume":"145","author":"J. Hu","year":"2023","unstructured":"J. Hu, X. Chen, Y. Luo, J. Yang, Q. Zeng, W. Luo et al., Renin-independent aldosteronism and chronic kidney disease in diabetes: Observational and Mendelian randomization analyses. Metabolism. 145, 155593 (2023). https:\/\/doi.org\/10.1016\/j.metabol.2023.155593","journal-title":"Metabolism"},{"key":"4593_CR42","doi-asserted-by":"publisher","first-page":"870047","DOI":"10.3389\/fendo.2022.870047","volume":"13","author":"W. Manosroi","year":"2022","unstructured":"W. Manosroi, P. Atthakomol, P. Wattanawitawas, S. Buranapin, Differences in Glycemic Abnormalities Between Primary Aldosteronism and Essential Hypertension: A Systematic Review and Meta-Analysis. Front. Endocrinol. (Lausanne). 13, 870047 (2022). https:\/\/doi.org\/10.3389\/fendo.2022.870047","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"4593_CR43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s2213-85871730319-4","volume":"6","author":"S. Monticone","year":"2018","unstructured":"S. Monticone, F. D\u2019Ascenzo, C. Moretti, T.A. Williams, F. Veglio, F. Gaita et al., Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 6(1), 41\u201350 (2018). https:\/\/doi.org\/10.1016\/s2213-85871730319-4","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"4593_CR44","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1097\/hjh.0000000000002441","volume":"38","author":"M. Parasiliti-Caprino","year":"2020","unstructured":"M. Parasiliti-Caprino, C. Lopez, N. Prencipe, B. Lucatello, F. Settanni, G. Giraudo et al., Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension. J. Hypertens. 38(9), 1841\u20131848 (2020). https:\/\/doi.org\/10.1097\/hjh.0000000000002441","journal-title":"J. Hypertens."},{"issue":"15","key":"4593_CR45","doi-asserted-by":"publisher","first-page":"e034180","DOI":"10.1161\/jaha.123.034180","volume":"13","author":"K. Inoue","year":"2024","unstructured":"K. Inoue, T. Naito, R. Fuji, K. Sonehara, K. Yamamoto, R. Baba et al., Primary Aldosteronism and Risk of Cardiovascular Outcomes: Genome-Wide Association and Mendelian Randomization Study. J. Am. Heart Assoc. 13(15), e034180 (2024). https:\/\/doi.org\/10.1161\/jaha.123.034180","journal-title":"J. Am. Heart Assoc."},{"key":"4593_CR46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.sleep.2023.12.007","volume":"114","author":"R. Zhang","year":"2024","unstructured":"R. Zhang, X. Cai, C. Lin, W. Yang, F. Lv, X. Han et al., Primary aldosteronism and obstructive sleep apnea: A meta-analysis of prevalence and metabolic characteristics. Sleep. Med. 114, 8\u201314 (2024). https:\/\/doi.org\/10.1016\/j.sleep.2023.12.007","journal-title":"Sleep. Med."},{"issue":"6","key":"4593_CR47","doi-asserted-by":"publisher","first-page":"E878","DOI":"10.1210\/jc.2010-2723","volume":"96","author":"N. Sonino","year":"2011","unstructured":"N. Sonino, E. Tomba, M.L. Genesia, C. Bertello, P. Mulatero, F. Veglio et al., Psychological assessment of primary aldosteronism: a controlled study. J. Clin. Endocrinol. Metab. 96(6), E878\u2013E883 (2011) https:\/\/doi.org\/10.1210\/jc.2010-2723","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"4593_CR48","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000093956","volume":"75","author":"N. Sonino","year":"2006","unstructured":"N. Sonino, F. Fallo, G.A. Fava, Psychological aspects of primary aldosteronism. Psychother. Psychosom. 75(5), 327\u2013330 (2006). https:\/\/doi.org\/10.1159\/000093956","journal-title":"Psychother. Psychosom."},{"issue":"2","key":"4593_CR49","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/cen.70051","volume":"104","author":"D. Oprea","year":"2026","unstructured":"D. Oprea, F. Lefran\u00e7ois, M. St-Jean, A.M. C\u00f4t\u00e9, M. Roy-Lacroix, M. Malick et al., A Retrospective Study on the Impact of Primary Aldosteronism in Pregnancy (H.A.P.P.I. Study Group). Clin. Endocrinol. (Oxf). 104(2), 113\u2013122 (2026). https:\/\/doi.org\/10.1111\/cen.70051","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"3","key":"4593_CR50","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.surg.2018.08.020","volume":"165","author":"C-H Chang","year":"2019","unstructured":"C.-H. Chang, S.-C.J. Chueh, V.-C. Wu, L. Chen, Y.-H. Lin, Y.-H. Hu et al., Risk of severe erectile dysfunction in primary hyperaldosteronism: A population-based propensity score matching cohort study. Surgery. 165(3), 622\u2013628 (2019). https:\/\/doi.org\/10.1016\/j.surg.2018.08.020","journal-title":"Surgery"},{"issue":"10","key":"4593_CR51","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.eprac.2025.06.015","volume":"31","author":"F. Fang","year":"2025","unstructured":"F. Fang, J. Lin, M. Li, Z. Wen, D. Mai, J. Liu et al., Effects of Plasma Aldosterone and Renin Concentrations With Blood Pressure Variation and Hypertension Risk in Chinese Adults: A Population-Based Hakka Biobank Study. Endocr. Pract. 31(10), 1265\u20131273 (2025). https:\/\/doi.org\/10.1016\/j.eprac.2025.06.015","journal-title":"Endocr. Pract."},{"issue":"1","key":"4593_CR52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1055\/a-2172-7228","volume":"56","author":"L. Chen","year":"2024","unstructured":"L. Chen, C. Adolf, M. Reincke, H. Schneider, Salt and Aldosterone - Reciprocal and Combined Effects in Preclinical Models and Humans. Horm. Metab. Res. 56(1), 99\u2013106 (2024). https:\/\/doi.org\/10.1055\/a-2172-7228","journal-title":"Horm. Metab. Res."},{"issue":"2","key":"4593_CR53","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/hr.2013.124","volume":"37","author":"T. Hattori","year":"2014","unstructured":"T. Hattori, T. Murase, Y. Sugiura, K. Nagasawa, K. Takahashi, M. Ohtake et al., Effects of salt status and blockade of mineralocorticoid receptors on aldosterone-induced cardiac injury. Hypertens. Res. 37(2), 125\u2013133 (2014). https:\/\/doi.org\/10.1038\/hr.2013.124","journal-title":"Hypertens. Res."},{"issue":"5","key":"4593_CR54","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1291\/hypres.28.447","volume":"28","author":"K. Yoshida","year":"2005","unstructured":"K. Yoshida, S. Kim-Mitsuyama, R. Wake, Y. Izumiya, Y. Izumi, T. Yukimura et al., Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. Hypertens. Res. 28(5), 447\u2013455 (2005). https:\/\/doi.org\/10.1291\/hypres.28.447","journal-title":"Hypertens. Res."},{"issue":"9","key":"4593_CR55","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1038\/s41440-025-02270-4","volume":"48","author":"X. Bu","year":"2025","unstructured":"X. Bu, F. Sun, Q. Li, H. Zhang, N. Jiang, Y. Luo et al., High salt intake exacerbates aldosterone-related target organ damage in patients with primary aldosteronism. Hypertens. Res. 48(9), 2339\u20132348 (2025). https:\/\/doi.org\/10.1038\/s41440-025-02270-4","journal-title":"Hypertens. Res."},{"issue":"3","key":"4593_CR56","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00424-014-1658-0","volume":"467","author":"J.W. Funder","year":"2015","unstructured":"J.W. Funder, Primary aldosteronism and salt. Pflugers Arch. 467(3), 587\u2013594 (2015). https:\/\/doi.org\/10.1007\/s00424-014-1658-0","journal-title":"Pflugers Arch."},{"issue":"6","key":"4593_CR57","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacc.2019.11.055","volume":"75","author":"F.J. He","year":"2020","unstructured":"F.J. He, M. Tan, Y. Ma, G.A. MacGregor, Salt Reduction to Prevent Hypertension and Cardiovascular Disease: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 75(6), 632\u2013647 (2020). https:\/\/doi.org\/10.1016\/j.jacc.2019.11.055","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"4593_CR58","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41440-022-01045-5","volume":"46","author":"Y. Yoshida","year":"2023","unstructured":"Y. Yoshida, R. Fujiki, M. Kinoshita, K. Sada, S. Miyamoto, Y. Ozeki et al., Importance of dietary salt restriction for patients with primary aldosteronism during treatment with mineralocorticoid receptor antagonists: The potential importance of post-treatment plasma renin levels. Hypertens. Res. 46(1), 100\u2013107 (2023). https:\/\/doi.org\/10.1038\/s41440-022-01045-5","journal-title":"Hypertens. Res."},{"issue":"1","key":"4593_CR59","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/joim.13618","volume":"294","author":"H. Schneider","year":"2023","unstructured":"H. Schneider, A.L. Sarkis, L. Sturm, V. Britz, A. Lechner, A.L. Potzel et al., Moderate dietary salt restriction improves blood pressure and mental well-being in patients with primary aldosteronism: The salt CONNtrol trial. J. Intern. Med. 294(1), 47\u201357 (2023). https:\/\/doi.org\/10.1111\/joim.13618","journal-title":"J. Intern. Med."},{"issue":"11","key":"4593_CR60","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1210\/jc.2016-1963","volume":"101","author":"R. Baudrand","year":"2016","unstructured":"R. Baudrand, F.J. Guarda, J. Torrey, G. Williams, A. Vaidya, Dietary Sodium Restriction Increases the Risk of Misinterpreting Mild Cases of Primary Aldosteronism. J. Clin. Endocrinol. Metab. 101(11), 3989\u20133996 (2016) https:\/\/doi.org\/10.1210\/jc.2016-1963","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"4593_CR61","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1161\/hypertensionaha.116.07615","volume":"68","author":"C. Catena","year":"2016","unstructured":"C. Catena, G. Colussi, M. Novello, N.D. Verheyen, N. Bertin, S. Pilz et al., Dietary Salt Intake Is a Determinant of Cardiac Changes After Treatment of Primary Aldosteronism: A Prospective Study. Hypertension. 68(1), 204\u2013212 (2016). https:\/\/doi.org\/10.1161\/hypertensionaha.116.07615","journal-title":"Hypertension"},{"issue":"1","key":"4593_CR62","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12020-016-0983-9","volume":"54","author":"C. Adolf","year":"2016","unstructured":"C. Adolf, E. Asbach, A.S. Dietz, K. Lang, S. Hahner, M. Quinkler et al., Worsening of lipid metabolism after successful treatment of primary aldosteronism. Endocrine. 54(1), 198\u2013205 (2016). https:\/\/doi.org\/10.1007\/s12020-016-0983-9","journal-title":"Endocrine"},{"issue":"3","key":"4593_CR63","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.diabet.2019.10.002","volume":"46","author":"H. Komada","year":"2020","unstructured":"H. Komada, Y. Hirota, A. So, T. Nakamura, Y. Okuno, H. Fukuoka et al., Insulin secretion and sensitivity before and after surgical treatment for aldosterone-producing adenoma. Diabetes Metab. 46(3), 236\u2013242 (2020). https:\/\/doi.org\/10.1016\/j.diabet.2019.10.002","journal-title":"Diabetes Metab."},{"issue":"1","key":"4593_CR64","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12902-022-01254-6","volume":"22","author":"Y. Liu","year":"2022","unstructured":"Y. Liu, L. Lin, C. Yuan, S. Shen, Y. Tang, Z. Liu et al., Recovery from diabetes mellitus in primary aldosteronism patients after adrenalectomy. BMC Endocr. Disord. 22(1), 331 (2022). https:\/\/doi.org\/10.1186\/s12902-022-01254-6","journal-title":"BMC Endocr. Disord"},{"issue":"1","key":"4593_CR65","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12020-022-03168-8","volume":"79","author":"M. Moustaki","year":"2023","unstructured":"M. Moustaki, S.A. Paschou, E.C. Vakali, A. Vryonidou, Secondary diabetes mellitus due to primary aldosteronism. Endocrine. 79(1), 17\u201330 (2023). https:\/\/doi.org\/10.1007\/s12020-022-03168-8","journal-title":"Endocrine"},{"key":"4593_CR66","doi-asserted-by":"publisher","unstructured":"R. Goto, T. Kondo, K. Ono, S. Kitano, N. Miyakawa, T. Watanabe et al., Mineralocorticoid Receptor May Regulate Glucose Homeostasis through the Induction of Interleukin-6 and Glucagon-Like peptide-1 in Pancreatic Islets. J. Clin. Med. 8(5) (2019). https:\/\/doi.org\/10.3390\/jcm8050674","DOI":"10.3390\/jcm8050674"},{"issue":"10","key":"4593_CR67","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/jhh.2014.19","volume":"28","author":"E.M. McMurray","year":"2014","unstructured":"E.M. McMurray, I.R. Wallace, C. Ennis, S.J. Hunter, A.B. Atkinson, P.M. Bell, Effect of eplerenone on insulin action in essential hypertension: a randomised, controlled, crossover study. J. Hum. Hypertens. 28(10), 575\u2013578 (2014). https:\/\/doi.org\/10.1038\/jhh.2014.19","journal-title":"J. Hum. Hypertens."},{"key":"4593_CR68","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.ijchy.2020.100029","volume":"5","author":"G.P. Rossi","year":"2020","unstructured":"G.P. Rossi, V. Bisogni, A.V. Bacca, A. Belfiore, M. Cesari, A. Concistr\u00e8 et al., The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. Int. J. Cardiol. Hypertens. 5, 100029 (2020). https:\/\/doi.org\/10.1016\/j.ijchy.2020.100029","journal-title":"Int. J. Cardiol. Hypertens."},{"issue":"2","key":"4593_CR69","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1093\/eurjpc\/zwaa108","volume":"29","author":"G.P. Rossi","year":"2022","unstructured":"G.P. Rossi, G. Rossitto, L. Amar, M. Azizi, A. Riester, M. Reincke et al., Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. Eur. J. Prev. Cardiol. 29(2), e85\u2013e93 (2022). https:\/\/doi.org\/10.1093\/eurjpc\/zwaa108","journal-title":"Eur. J. Prev. Cardiol."},{"key":"4593_CR70","doi-asserted-by":"publisher","unstructured":"J. Goi, M. Paja Fano, A. Rizo Gellida, M. Gonz\u00e1lez-Boillos, P. Mart\u00edn Rojas-Marcos, L. Caja Guayerbas et al., Mineralocorticoid receptor antagonist pre-adrenalectomy in primary aldosteronism. J Clin Endocrinol Metab. 2025. https:\/\/doi.org\/10.1210\/clinem\/dgaf545","DOI":"10.1210\/clinem\/dgaf545"},{"issue":"3","key":"4593_CR71","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1161\/hypertensionaha.118.11568","volume":"72","author":"G.L. Hundemer","year":"2018","unstructured":"G.L. Hundemer, G.C. Curhan, N. Yozamp, M. Wang, A. Vaidya, Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism. Hypertension. 72(3), 658\u2013666 (2018). https:\/\/doi.org\/10.1161\/hypertensionaha.118.11568","journal-title":"Hypertension"},{"issue":"3","key":"4593_CR72","doi-asserted-by":"publisher","first-page":"e1280","DOI":"10.1210\/clinem\/dgad654","volume":"109","author":"S. Samnani","year":"2024","unstructured":"S. Samnani, I. Cenzer, G.A. Kline, S.J. Lee, G.L. Hundemer, C. McClurg et al., Time to Benefit of Surgery vs Targeted Medical Therapy for Patients With Primary Aldosteronism: A Meta-analysis. J. Clin. Endocrinol. Metab. 109(3), e1280\u2013e9 (2024). https:\/\/doi.org\/10.1210\/clinem\/dgad654","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"4593_CR73","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1161\/hypertensionaha.123.21474","volume":"80","author":"D.L. Cohen","year":"2023","unstructured":"D.L. Cohen, H. Wachtel, A. Vaidya, G.L. Hundemer, Y. Tezuka, A. Davio et al., Primary Aldosteronism in Chronic Kidney Disease: Blood Pressure Control and Kidney and Cardiovascular Outcomes After Surgical Versus Medical Management. Hypertension. 80(10), 2187\u20132195 (2023). https:\/\/doi.org\/10.1161\/hypertensionaha.123.21474","journal-title":"Hypertension"},{"issue":"10","key":"4593_CR74","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1097\/hjh.0000000000003813","volume":"42","author":"M. Araujo-Castro","year":"2024","unstructured":"M. Araujo-Castro, M. Paja Fano, M. Gonz\u00e1lez-Boillos, E. Pascual-Corrales, P. Mart\u00edn, A. Rojas-Marcos, Garc\u00eda-Cano et al., Impact of primary aldosteronism on kidney function: results from the SPAIN-ALDO registry. J. Hypertens. 42(10), 1805\u20131812 (2024). https:\/\/doi.org\/10.1097\/hjh.0000000000003813","journal-title":"J. Hypertens."},{"issue":"9","key":"4593_CR75","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1097\/hjh.0000000000003479","volume":"41","author":"J.Y. Sheu","year":"2023","unstructured":"J.Y. Sheu, S.M. Wang, V.C. Wu, K.H. Huang, C.S. Tseng, Y.J. Lee et al., Estimated glomerular filtration rate-dip after medical target therapy associated with increased mortality and cardiovascular events in patients with primary aldosteronism. J. Hypertens. 41(9), 1401\u20131410 (2023). https:\/\/doi.org\/10.1097\/hjh.0000000000003479","journal-title":"J. Hypertens."},{"key":"4593_CR76","doi-asserted-by":"publisher","unstructured":"K.A. Stahl, K.M. Ramonell, A. Puli, P.K. Fazeli, K.L. McCoy, S.E. Carty et al., Renal function after adrenalectomy in patients with primary aldosteronism. Surgery. 2025:109761. https:\/\/doi.org\/10.1016\/j.surg.2025.109761","DOI":"10.1016\/j.surg.2025.109761"},{"issue":"3","key":"4593_CR77","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1161\/hypertensionaha.119.13131","volume":"74","author":"H. Kobayashi","year":"2019","unstructured":"H. Kobayashi, M. Abe, Y. Nakamura, K. Takahashi, M. Fujita, Y. Takeda et al., Association Between Acute Fall in Estimated Glomerular Filtration Rate After Treatment for Primary Aldosteronism and Long-Term Decline in Renal Function. Hypertension. 74(3), 630\u2013638 (2019). https:\/\/doi.org\/10.1161\/hypertensionaha.119.13131","journal-title":"Hypertension"},{"issue":"5","key":"4593_CR78","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1210\/jc.2013-2180","volume":"99","author":"Y. Iwakura","year":"2014","unstructured":"Y. Iwakura, R. Morimoto, M. Kudo, Y. Ono, K. Takase, K. Seiji et al., Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J. Clin. Endocrinol. Metab. 99(5), 1593\u20131598 (2014) https:\/\/doi.org\/10.1210\/jc.2013-2180","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"4593_CR79","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41440-023-01412-w","volume":"47","author":"Y. Yoshida","year":"2024","unstructured":"Y. Yoshida, M. Fujiwara, M. Kinoshita, K. Sada, S. Miyamoto, Y. Ozeki et al., Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism. Hypertens. Res. 47(1), 157\u2013167 (2024). https:\/\/doi.org\/10.1038\/s41440-023-01412-w","journal-title":"Hypertens. Res."},{"key":"4593_CR80","doi-asserted-by":"publisher","first-page":"6453933","DOI":"10.1155\/2023\/6453933","volume":"2023","author":"M. Fujimoto","year":"2023","unstructured":"M. Fujimoto, S. Watanabe, K. Igarashi, Y. Ruike, K. Ishiwata, K. Naito et al., Antihypertensive Effects of Esaxerenone in Older Patients with Primary Aldosteronism. Int. J. Hypertens. 2023, 6453933 (2023). https:\/\/doi.org\/10.1155\/2023\/6453933","journal-title":"Int. J. Hypertens."},{"key":"4593_CR81","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.125.25104","author":"L. Marzano","year":"2025","unstructured":"L. Marzano, F. Zoccatelli, F. Pizzolo, S. Friso, Adrenalectomy Versus Medical Therapy in Primary Aldosteronism: A Meta-Analysis of Long-Term Cardiac Remodeling and Function: Medical Versus Adrenalectomy Treatment Compared in Hyperaldosteronism (MATCH) Study. Hypertension. (2025). https:\/\/doi.org\/10.1161\/hypertensionaha.125.25104","journal-title":"Hypertension"},{"issue":"4","key":"4593_CR82","first-page":"2689","volume":"14","author":"Z Chen","year":"2022","unstructured":"Z. Chen, Z. Zhang, Q. Xi, G. Huang, L. Wang, Curable congestive heart failure in patients with primary aldosteronism: two cases reports. Am. J. Transl Res. 14(4), 2689\u20132696 (2022)","journal-title":"Am. J. Transl Res."},{"issue":"1","key":"4593_CR83","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12902-023-01503-2","volume":"23","author":"S. Hoshi","year":"2023","unstructured":"S. Hoshi, A. Onagi, R. Tanji, R. Honda-Takinami, K. Matsuoka, J. Hata et al., Unilateral adrenalectomy for a drug-resistant bilateral primary aldosteronism with heart failure: pathophysiology and surgical indication. BMC Endocr. Disord. 23(1), 243 (2023). https:\/\/doi.org\/10.1186\/s12902-023-01503-2","journal-title":"BMC Endocr. Disord"},{"issue":"4","key":"4593_CR84","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/hypertensionaha.117.10596","volume":"71","author":"G.P. Rossi","year":"2018","unstructured":"G.P. Rossi, G. Maiolino, A. Flego, A. Belfiore, G. Bernini, B. Fabris et al., Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term. Hypertension. 71(4), 585\u2013591 (2018). https:\/\/doi.org\/10.1161\/hypertensionaha.117.10596","journal-title":"Hypertension"},{"key":"4593_CR85","doi-asserted-by":"publisher","unstructured":"N. Qian, J. Xu, Y. Wang, Stroke Risks in Primary Aldosteronism with Different Treatments: A Systematic Review and Meta-Analysis. J. Cardiovasc. Dev. Dis. 9(9) (2022). https:\/\/doi.org\/10.3390\/jcdd9090300","DOI":"10.3390\/jcdd9090300"},{"issue":"6","key":"4593_CR86","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1530\/eje-22-0375","volume":"187","author":"S.Y. Chen","year":"2022","unstructured":"S.Y. Chen, J.Y. Chen, W.C. Huang, T.H.K. Puar, P. Chin Kek, J.S. Chueh et al., Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis. Eur. J. Endocrinol. 187(6), S47\u2013s58 (2022). https:\/\/doi.org\/10.1530\/eje-22-0375","journal-title":"Eur. J. Endocrinol."},{"issue":"11","key":"4593_CR87","doi-asserted-by":"publisher","first-page":"7367","DOI":"10.1097\/js9.0000000000002048","volume":"110","author":"S.S. Nayak","year":"2024","unstructured":"S.S. Nayak, E. Amini-Salehi, F. Joukar, P. Biswas, S. Nobakht, N. Letafatkar et al., Cardiovascular and all-cause mortality outcomes of adrenalectomy versus medical treatment in primary aldosteronism: an umbrella review. Int. J. Surg. 110(11), 7367\u20137380 (2024). https:\/\/doi.org\/10.1097\/js9.0000000000002048","journal-title":"Int. J. Surg."},{"issue":"5","key":"4593_CR88","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1530\/eje-21-0018","volume":"185","author":"A. K\u00f6hler","year":"2021","unstructured":"A. K\u00f6hler, A.L. Sarkis, D.A. Heinrich, L. M\u00fcller, L. Handgriff, S. Deniz et al., Renin, a marker for left ventricular hypertrophy, in primary aldosteronism: a cohort study. Eur. J. Endocrinol. 185(5), 663\u2013672 (2021). https:\/\/doi.org\/10.1530\/eje-21-0018","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"4593_CR89","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","volume":"6","author":"G.L. Hundemer","year":"2018","unstructured":"G.L. Hundemer, G.C. Curhan, N. Yozamp, M. Wang, A. Vaidya, Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 6(1), 51\u201359 (2018) https:\/\/doi.org\/10.1016\/s2213-85871730367-4","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"8","key":"4593_CR90","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","volume":"3","author":"G.L. Hundemer","year":"2018","unstructured":"G.L. Hundemer, G.C. Curhan, N. Yozamp, M. Wang, A. Vaidya, Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism. JAMA Cardiol. 3(8), 768\u2013774 (2018). https:\/\/doi.org\/10.1001\/jamacardio.2018.2003","journal-title":"JAMA Cardiol."},{"issue":"3","key":"4593_CR91","doi-asserted-by":"publisher","first-page":"e038714","DOI":"10.1161\/JAHA.124.038714","volume":"14","author":"C.W. Huang","year":"2025","unstructured":"C.W. Huang, T.Y. Huang, Y.F. Yang, L.Y. Chang, Y.K. Tu, V.C. Wu et al., Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta-Analysis. J. Am. Heart Association. 14(3), e038714 (2025). https:\/\/doi.org\/10.1161\/JAHA.124.038714","journal-title":"J. Am. Heart Association"},{"issue":"8","key":"4593_CR92","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1530\/ec-21-0125","volume":"10","author":"Y.K. Tan","year":"2021","unstructured":"Y.K. Tan, Y.H. Kwan, D.C.L. Teo, M. Velema, J. Deinum, P.T. Tan et al., Improvement in quality of life and psychological symptoms after treatment for primary aldosteronism: Asian Cohort Study. Endocr. Connect. 10(8), 834\u2013844 (2021). https:\/\/doi.org\/10.1530\/ec-21-0125","journal-title":"Endocr. Connect."},{"key":"4593_CR93","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jpsychires.2021.02.064","volume":"137","author":"H. Murck","year":"2021","unstructured":"H. Murck, C. Adolf, A. Schneider, L. Schlageter, D. Heinrich, K. Ritzel et al., Differential effects of reduced mineralocorticoid receptor activation by unilateral adrenalectomy vs mineralocorticoid antagonist treatment in patients with primary aldosteronism - Implications for depression and anxiety. J. Psychiatr Res. 137, 376\u2013382 (2021). https:\/\/doi.org\/10.1016\/j.jpsychires.2021.02.064","journal-title":"J. Psychiatr Res."},{"issue":"9","key":"4593_CR94","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1161\/hypertensionaha.121.18858","volume":"79","author":"V. Sanga","year":"2022","unstructured":"V. Sanga, G. Rossitto, T.M. Seccia, G.P. Rossi, Management and Outcomes of Primary Aldosteronism in Pregnancy: A Systematic Review. Hypertension. 79(9), 1912\u20131921 (2022). https:\/\/doi.org\/10.1161\/hypertensionaha.121.18858","journal-title":"Hypertension"},{"issue":"3","key":"4593_CR95","doi-asserted-by":"publisher","first-page":"H670","DOI":"10.1152\/ajpheart.00419.2023","volume":"326","author":"S. Verma","year":"2024","unstructured":"S. Verma, A. Pandey, A.K. Pandey, J. Butler, J.S. Lee, H. Teoh et al., Aldosterone and aldosterone synthase inhibitors in cardiorenal disease. Am. J. Physiol. Heart Circ. Physiol. 326(3), H670\u2013h88 (2024). https:\/\/doi.org\/10.1152\/ajpheart.00419.2023","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"4593_CR96","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/cvr\/cvac027","volume":"119","author":"W.W. Parksook","year":"2023","unstructured":"W.W. Parksook, G.H. Williams, Aldosterone and cardiovascular diseases. Cardiovasc. Res. 119(1), 28\u201344 (2023). https:\/\/doi.org\/10.1093\/cvr\/cvac027","journal-title":"Cardiovasc. Res."},{"issue":"5","key":"4593_CR97","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jacc.2025.06.012","volume":"86","author":"F. Fioretti","year":"2025","unstructured":"F. Fioretti, J.M. Testani, M.C. Tio, B. Pitt, J. Butler, Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases. J. Am. Coll. Cardiol. 86(5), 354\u2013373 (2025). https:\/\/doi.org\/10.1016\/j.jacc.2025.06.012","journal-title":"J. Am. Coll. Cardiol."},{"key":"4593_CR98","doi-asserted-by":"publisher","unstructured":"J. Barrera-Chimal, A. Vaidya, F. Jaisser, Aldosterone synthase inhibition: a novel bullet to fight cardiovascular-kidney-metabolic syndrome. J. Mol. Endocrinol. 75(3) (2025). https:\/\/doi.org\/10.1530\/jme-25-0047","DOI":"10.1530\/jme-25-0047"},{"issue":"1","key":"4593_CR99","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12967-025-06329-1","volume":"23","author":"X. Li","year":"2025","unstructured":"X. Li, M. Luo, Y. Zeng, R. Zhang, X. Lin, Y. Du et al., MicroRNA-24-3p targeting Top1 in perirenal fat is involved in circulating inflammation and high cardiovascular disease risk in patients with primary aldosteronism. J. Transl Med. 23(1), 345 (2025). https:\/\/doi.org\/10.1186\/s12967-025-06329-1","journal-title":"J. Transl Med."},{"issue":"6","key":"4593_CR100","doi-asserted-by":"publisher","first-page":"H1253","DOI":"10.1152\/ajpheart.00829.2024","volume":"328","author":"R.M. Costa","year":"2025","unstructured":"R.M. Costa, A. Bruder-Nascimento, J.V. Alves, W.M.C. Awata, S. Singh, D. Rodrigues et al., Beclin-1-dependent autophagy protects perivascular adipose tissue function from hyperaldosteronism effects. Am. J. Physiol. Heart Circ. Physiol. 328(6), H1253\u2013h66 (2025). https:\/\/doi.org\/10.1152\/ajpheart.00829.2024","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"23","key":"4593_CR101","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1161\/circulationaha.116.024369","volume":"134","author":"T. Bruder-Nascimento","year":"2016","unstructured":"T. Bruder-Nascimento, N.S. Ferreira, C.Z. Zanotto, F. Ramalho, I.O. Pequeno, V.C. Olivon et al., NLRP3 Inflammasome Mediates Aldosterone-Induced Vascular Damage. Circulation. 134(23), 1866\u20131880 (2016). https:\/\/doi.org\/10.1161\/circulationaha.116.024369","journal-title":"Circulation"},{"issue":"9","key":"4593_CR102","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1096\/fj.15-271734","volume":"29","author":"H. Kadoya","year":"2015","unstructured":"H. Kadoya, M. Satoh, T. Sasaki, S. Taniguchi, M. Takahashi, N. Kashihara, Excess aldosterone is a critical danger signal for inflammasome activation in the development of renal fibrosis in mice. Faseb j. 29(9), 3899\u20133910 (2015). https:\/\/doi.org\/10.1096\/fj.15-271734","journal-title":"Faseb j."},{"issue":"5","key":"4593_CR103","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/s0002-94401064454-9","volume":"161","author":"Y. Sun","year":"2002","unstructured":"Y. Sun, J. Zhang, L. Lu, S.S. Chen, M.T. Quinn, K.T. Weber, Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am. J. Pathol. 161(5), 1773\u20131781 (2002). https:\/\/doi.org\/10.1016\/s0002-94401064454-9","journal-title":"Am. J. Pathol."},{"key":"4593_CR104","doi-asserted-by":"publisher","first-page":"123627","DOI":"10.1016\/j.lfs.2025.123627","volume":"372","author":"R. Lv","year":"2025","unstructured":"R. Lv, Z. Liu, H. Guo, B. Zhang, X. Wang, Y. Peng et al., Fibroblast to macrophage-like cell transition in renal inflammatory injury through the MR\/CSF1 pathway induced by aldosterone. Life Sci. 372, 123627 (2025). https:\/\/doi.org\/10.1016\/j.lfs.2025.123627","journal-title":"Life Sci."},{"issue":"2","key":"4593_CR105","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nm1545","volume":"13","author":"J.A. Leopold","year":"2007","unstructured":"J.A. Leopold, A. Dam, B.A. Maron, A.W. Scribner, R. Liao, D.E. Handy et al., Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat. Med. 13(2), 189\u2013197 (2007). https:\/\/doi.org\/10.1038\/nm1545","journal-title":"Nat. Med."},{"issue":"7","key":"4593_CR106","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1093\/cvr\/cvy092","volume":"114","author":"C. van Heijden","year":"2018","unstructured":"van C. Heijden, J. Deinum, L.A.B. Joosten, M.G. Netea, N.P. Riksen, The mineralocorticoid receptor as a modulator of innate immunity and atherosclerosis. Cardiovasc. Res. 114(7), 944\u2013953 (2018). https:\/\/doi.org\/10.1093\/cvr\/cvy092","journal-title":"Cardiovasc. Res."},{"key":"4593_CR107","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.clnu.2024.12.011","volume":"44","author":"Q. Zeng","year":"2025","unstructured":"Q. Zeng, X. Luo, X. Chen, W. Luo, R. Li, S. Yang et al., Renin-independent aldosteronism and metabolic dysfunction-associated steatotic liver disease and cirrhosis: A genetic association study. Clin. Nutr. 44, 193\u2013200 (2025). https:\/\/doi.org\/10.1016\/j.clnu.2024.12.011","journal-title":"Clin. Nutr."},{"issue":"3","key":"4593_CR108","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"EASL-EASD-EASO","year":"2024","unstructured":"EASL-EASD-EASO, Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81(3), 492\u2013542 (2024). https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","journal-title":"J. Hepatol."},{"issue":"5","key":"4593_CR109","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1210\/en.2009-0869","volume":"151","author":"T. Wada","year":"2010","unstructured":"T. Wada, H. Kenmochi, Y. Miyashita, M. Sasaki, M. Ojima, M. Sasahara et al., Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology. 151(5), 2040\u20132049 (2010). https:\/\/doi.org\/10.1210\/en.2009-0869","journal-title":"Endocrinology"},{"issue":"17","key":"4593_CR110","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1161\/circulationaha.107.748640","volume":"117","author":"C. Guo","year":"2008","unstructured":"C. Guo, V. Ricchiuti, B.Q. Lian, T.M. Yao, P. Coutinho, J.R. Romero et al., Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 117(17), 2253\u20132261 (2008). https:\/\/doi.org\/10.1161\/circulationaha.107.748640","journal-title":"Circulation"},{"key":"4593_CR111","doi-asserted-by":"publisher","unstructured":"G.M. Kuster, E. Kotlyar, M.K. Rude, D.A. Siwik, R. Liao, W.S. Colucci et al., Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111(4):420\u2009\u2013\u20097. https:\/\/doi.org\/10.1161\/01.Cir.0000153800.09920.40","DOI":"10.1161\/01.Cir.0000153800.09920.40"},{"issue":"5","key":"4593_CR112","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"E.R. Blasi","year":"2003","unstructured":"E.R. Blasi, R. Rocha, A.E. Rudolph, E.A. Blomme, M.L. Polly, E.G. McMahon, Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 63(5), 1791\u20131800 (2003). https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00929.x","journal-title":"Kidney Int."},{"issue":"1","key":"4593_CR113","doi-asserted-by":"publisher","first-page":"E110","DOI":"10.1152\/ajpendo.00258.2007","volume":"295","author":"G. Lastra","year":"2008","unstructured":"G. Lastra, A. Whaley-Connell, C. Manrique, J. Habibi, A.A. Gutweiler, L. Appesh et al., Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am. J. Physiol. Endocrinol. Metab. 295(1), E110\u2013E116 (2008). https:\/\/doi.org\/10.1152\/ajpendo.00258.2007","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"5","key":"4593_CR114","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1161\/hypertensionaha.119.13922","volume":"75","author":"G.K. Adler","year":"2020","unstructured":"G.K. Adler, G.R. Murray, A.F. Turcu, H. Nian, C. Yu, C.C. Solorzano et al., Primary Aldosteronism Decreases Insulin Secretion and Increases Insulin Clearance in Humans. Hypertension. 75(5), 1251\u20131259 (2020). https:\/\/doi.org\/10.1161\/hypertensionaha.119.13922","journal-title":"Hypertension"},{"issue":"1\u20132","key":"4593_CR115","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11010-012-1452-2","volume":"372","author":"J. Selvaraj","year":"2013","unstructured":"J. Selvaraj, S. Sathish, C. Mayilvanan, K. Balasubramanian, Excess aldosterone-induced changes in insulin signaling molecules and glucose oxidation in gastrocnemius muscle of adult male rat. Mol. Cell. Biochem. 372(1\u20132), 113\u2013126 (2013). https:\/\/doi.org\/10.1007\/s11010-012-1452-2","journal-title":"Mol. Cell. Biochem."},{"issue":"1","key":"4593_CR116","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.mce.2012.02.007","volume":"355","author":"T.A. Williams","year":"2012","unstructured":"T.A. Williams, S. Monticone, R. Urbanet, C. Bertello, G. Giraudo, R. Vettor et al., Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. Mol. Cell. Endocrinol. 355(1), 162\u2013168 (2012). https:\/\/doi.org\/10.1016\/j.mce.2012.02.007","journal-title":"Mol. Cell. Endocrinol."},{"issue":"2","key":"4593_CR117","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/atvbaha.111.240697","volume":"32","author":"S.J. Sherajee","year":"2012","unstructured":"S.J. Sherajee, Y. Fujita, K. Rafiq, D. Nakano, H. Mori, T. Masaki et al., Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor. Arterioscler. Thromb. Vasc Biol. 32(2), 257\u2013263 (2012). https:\/\/doi.org\/10.1161\/atvbaha.111.240697","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"issue":"4","key":"4593_CR118","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1161\/hypertensionaha.107.093955","volume":"50","author":"H. Hitomi","year":"2007","unstructured":"H. Hitomi, H. Kiyomoto, A. Nishiyama, T. Hara, K. Moriwaki, K. Kaifu et al., Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension. 50(4), 750\u2013755 (2007). https:\/\/doi.org\/10.1161\/hypertensionaha.107.093955","journal-title":"Hypertension"},{"key":"4593_CR119","doi-asserted-by":"publisher","first-page":"13215","DOI":"10.1038\/srep13215","volume":"5","author":"F. Chen","year":"2015","unstructured":"F. Chen, J. Liu, Y. Wang, T. Wu, W. Shan, Y. Zhu et al., Aldosterone induces clonal \u03b2-cell failure through glucocorticoid receptor. Sci. Rep. 5, 13215 (2015). https:\/\/doi.org\/10.1038\/srep13215","journal-title":"Sci. Rep."},{"issue":"1","key":"4593_CR120","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1161\/01.HYP.0000226054.53527.bb","volume":"48","author":"D. Nagata","year":"2006","unstructured":"D. Nagata, M. Takahashi, K. Sawai, T. Tagami, T. Usui, A. Shimatsu et al., Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension. 48(1), 165\u2013171 (2006). https:\/\/doi.org\/10.1161\/01.HYP.0000226054.53527.bb","journal-title":"Hypertension"},{"issue":"5","key":"4593_CR121","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/hypertensionaha.123.21358","volume":"81","author":"N.D. Camarda","year":"2024","unstructured":"N.D. Camarda, J. Ibarrola, L.A. Biwer, I.Z. Jaffe, Mineralocorticoid Receptors in Vascular Smooth Muscle: Blood Pressure and Beyond. Hypertension. 81(5), 1008\u20131020 (2024). https:\/\/doi.org\/10.1161\/hypertensionaha.123.21358","journal-title":"Hypertension"},{"key":"4593_CR122","doi-asserted-by":"publisher","first-page":"917356","DOI":"10.3389\/fendo.2022.917356","volume":"13","author":"X. Chang","year":"2022","unstructured":"X. Chang, J. Hao, X. Wang, J. Liu, J. Ni, L. Hao, The Role of AIF-1 in the Aldosterone-Induced Vascular Calcification Related to Chronic Kidney Disease: Evidence From Mice Model and Cell Co-Culture Model. Front. Endocrinol. (Lausanne). 13, 917356 (2022). https:\/\/doi.org\/10.3389\/fendo.2022.917356","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"4593_CR123","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jchf.2014.08.002","volume":"3","author":"L. Calvier","year":"2015","unstructured":"L. Calvier, E. Martinez-Martinez, M. Miana, V. Cachofeiro, E. Rousseau, J.R. S\u00e1daba et al., The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail. 3(1), 59\u201367 (2015). https:\/\/doi.org\/10.1016\/j.jchf.2014.08.002","journal-title":"JACC Heart Fail."},{"issue":"4","key":"4593_CR124","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/01.Hyp.0000174593.88899.68","volume":"46","author":"Y. Nagai","year":"2005","unstructured":"Y. Nagai, K. Miyata, G.P. Sun, M. Rahman, S. Kimura, A. Miyatake et al., Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1\/2 in rat renal fibroblasts. Hypertension. 46(4), 1039\u20131045 (2005). https:\/\/doi.org\/10.1161\/01.Hyp.0000174593.88899.68","journal-title":"Hypertension"},{"key":"4593_CR125","doi-asserted-by":"publisher","first-page":"1567876","DOI":"10.3389\/fendo.2025.1567876","volume":"16","author":"Y.L. Chen","year":"2025","unstructured":"Y.L. Chen, C.H. Chen, X.F. Ye, J.Z. Xu, L.M. Zhu, T.Y. Xu et al., Myocardial fibrosis in primary aldosteronism. Front. Endocrinol. (Lausanne). 16, 1567876 (2025). https:\/\/doi.org\/10.3389\/fendo.2025.1567876","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"4593_CR126","doi-asserted-by":"publisher","first-page":"672557","DOI":"10.3389\/fendo.2021.672557","volume":"12","author":"F. Zhou","year":"2021","unstructured":"F. Zhou, T. Wu, W. Wang, W. Cheng, S. Wan, H. Tian et al., CMR-Verified Myocardial Fibrosis Is Associated With Subclinical Diastolic Dysfunction in Primary Aldosteronism Patients. Front. Endocrinol. (Lausanne). 12, 672557 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.672557","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"6","key":"4593_CR127","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","volume":"96","author":"I.Z. Jaffe","year":"2005","unstructured":"I.Z. Jaffe, M.E. Mendelsohn, Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ. Res. 96(6), 643\u2013650 (2005). https:\/\/doi.org\/10.1161\/01.RES.0000159937.05502.d1","journal-title":"Circ. Res."},{"issue":"16","key":"4593_CR128","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1093\/eurheartj\/ehr266","volume":"33","author":"J.C. Reil","year":"2012","unstructured":"J.C. Reil, M. Hohl, S. Selejan, P. Lipp, F. Drautz, A. Kazakow et al., Aldosterone promotes atrial fibrillation. Eur. Heart J. 33(16), 2098\u20132108 (2012). https:\/\/doi.org\/10.1093\/eurheartj\/ehr266","journal-title":"Eur. Heart J."},{"issue":"22","key":"4593_CR129","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1161\/circulationaha.115.018226","volume":"132","author":"A.C. Huby","year":"2015","unstructured":"A.C. Huby, G. Antonova, J. Groenendyk, C.E. Gomez-Sanchez, W.B. Bollag, J.A. Filosa et al., Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis. Circulation. 132(22), 2134\u20132145 (2015). https:\/\/doi.org\/10.1161\/circulationaha.115.018226","journal-title":"Circulation"},{"issue":"1","key":"4593_CR130","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/hr.2011.173","volume":"35","author":"G.Z. Kalil","year":"2012","unstructured":"G.Z. Kalil, W.G. Haynes, Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. Hypertens. Res. 35(1), 4\u201316 (2012). https:\/\/doi.org\/10.1038\/hr.2011.173","journal-title":"Hypertens. Res."},{"issue":"5","key":"4593_CR131","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/hypertensionaha.111.190223","volume":"59","author":"A.M. Briones","year":"2012","unstructured":"A.M. Briones, A. Nguyen Dinh Cat, G.E. Callera, A. Yogi, D. Burger, Y. He et al., Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 59(5), 1069\u20131078 (2012). https:\/\/doi.org\/10.1161\/hypertensionaha.111.190223","journal-title":"Hypertension"},{"issue":"5","key":"4593_CR132","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/sj.ijo.0803508","volume":"31","author":"S. Schinner","year":"2007","unstructured":"S. Schinner, H.S. Willenberg, D. Krause, M. Schott, V. Lamounier-Zepter, A.W. Krug et al., Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int. J. Obes. (Lond). 31(5), 864\u2013870 (2007). https:\/\/doi.org\/10.1038\/sj.ijo.0803508","journal-title":"Int. J. Obes. (Lond)"},{"key":"4593_CR133","doi-asserted-by":"publisher","unstructured":"N. Ekman, A.B. Grossman, A. Nieckarz, \u0141. J\u0119drzejewski, J. Wolf, D. Dworakowska, Non-Hypertensive Effects of Aldosterone. Int. J. Mol. Sci. 26(2) (2025). https:\/\/doi.org\/10.3390\/ijms26020540","DOI":"10.3390\/ijms26020540"},{"issue":"4","key":"4593_CR134","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1507\/endocrj.EJ21-0508","volume":"69","author":"M. Naruse","year":"2022","unstructured":"M. Naruse, T. Katabami, H. Shibata, M. Sone, K. Takahashi, A. Tanabe et al., Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr. J. 69(4), 327\u2013359 (2022). https:\/\/doi.org\/10.1507\/endocrj.EJ21-0508","journal-title":"Endocr. J."},{"issue":"9","key":"4593_CR135","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1161\/hypertensionaha.124.22642","volume":"81","author":"G.P. Rossi","year":"2024","unstructured":"G.P. Rossi, F.B. Rossi, C. Guarnieri, G. Rossitto, T.M. Seccia, Clinical Management of Primary Aldosteronism: An Update. Hypertension. 81(9), 1845\u20131856 (2024). https:\/\/doi.org\/10.1161\/hypertensionaha.124.22642","journal-title":"Hypertension"},{"key":"4593_CR136","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-024-09081-2","author":"S. Bansal","year":"2024","unstructured":"S. Bansal, H. Puzantian, R.R. Townsend, Rising Prevalence of Obesity and Primary Hyperaldosteronism: Co-incidence or Connected Circumstances Leading to Hypertension? A Narrative Review. J. Gen. Intern. Med. (2024). https:\/\/doi.org\/10.1007\/s11606-024-09081-2","journal-title":"J. Gen. Intern. Med."},{"issue":"1","key":"4593_CR137","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/labmed\/lmae065","volume":"56","author":"D. Chen","year":"2025","unstructured":"D. Chen, Y. Li, J. Wu, W. Lin, L. Zhong, P. Feng et al., Extra cut-off value of aldosterone-to-renin ratio for screening primary aldosteronism in hypertensive patients with diabetes mellitus. Lab. Med. 56(1), 49\u201354 (2025). https:\/\/doi.org\/10.1093\/labmed\/lmae065","journal-title":"Lab. Med."},{"key":"4593_CR138","doi-asserted-by":"publisher","first-page":"1383567","DOI":"10.3389\/fcvm.2024.1383567","volume":"11","author":"D. Yan","year":"2024","unstructured":"D. Yan, X. Zou, X. Li, Q. Zeng, H. He, J. Guo et al., Screening parameters for diagnosing primary aldosteronism in patients with moderate to severe obstructive sleep apnea hypopnea syndrome and resistant hypertension. Front. Cardiovasc. Med. 11, 1383567 (2024). https:\/\/doi.org\/10.3389\/fcvm.2024.1383567","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"4593_CR139","doi-asserted-by":"publisher","first-page":"2301571","DOI":"10.1080\/10641963.2023.2301571","volume":"46","author":"C. He","year":"2024","unstructured":"C. He, R. Li, J. Yang, H. Shen, Y. Wang, X. Chen et al., Optimizing the aldosterone-to-renin ratio cut-off for screening primary aldosteronism based on cardiovascular risk: a collaborative study. Clin. Exp. Hypertens. 46(1), 2301571 (2024). https:\/\/doi.org\/10.1080\/10641963.2023.2301571","journal-title":"Clin. Exp. Hypertens."},{"issue":"11","key":"4593_CR140","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/s2213-85872200253-4","volume":"10","author":"T.A. Williams","year":"2022","unstructured":"T.A. Williams, S. Gong, Y. Tsurutani, Y. Tezuka, M. Thuzar, J. Burrello et al., Adrenal surgery for bilateral primary aldosteronism: an international retrospective cohort study. Lancet Diabetes Endocrinol. 10(11), 769\u2013771 (2022). https:\/\/doi.org\/10.1016\/s2213-85872200253-4","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"4593_CR141","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/hjh.0000000000002216","volume":"38","author":"S. Monticone","year":"2020","unstructured":"S. Monticone, E. Sconfienza, F. D\u2019Ascenzo, F. Buffolo, F. Satoh, L.A. Sechi et al., Renal damage in primary aldosteronism: a systematic review and meta-analysis. J. Hypertens. 38(1), 3\u201312 (2020). https:\/\/doi.org\/10.1097\/hjh.0000000000002216","journal-title":"J. Hypertens."},{"issue":"11","key":"4593_CR142","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s40265-024-02092-7","volume":"84","author":"X. Yi","year":"2024","unstructured":"X. Yi, S. Yang, J. Yang, X. Chen, A. Zhang, Q. Zeng et al., Renin-Angiotensin-Aldosterone System Modulators in Adults with Hypertension: A Network Meta-Analysis of Randomized Controlled Trials. Drugs. 84(11), 1445\u20131462 (2024). https:\/\/doi.org\/10.1007\/s40265-024-02092-7","journal-title":"Drugs"},{"key":"4593_CR143","doi-asserted-by":"publisher","unstructured":"J. Hu, Q. Zhou, Y. Sun, Z. Feng, J. Yang, W. He et al., Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: A Pilot Randomized Controlled Trial. Circulation. 2025;151(2):196\u2009\u2013\u20098. https:\/\/doi.org\/10.1161\/circulationaha.124.071452","DOI":"10.1161\/circulationaha.124.071452"},{"issue":"8","key":"4593_CR144","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1681\/asn.2022020207","volume":"33","author":"M. Provenzano","year":"2022","unstructured":"M. Provenzano, M.J. Puchades, C. Garofalo, N. Jongs, L. D\u2019Marco, M. Andreucci et al., Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial. J. Am. Soc. Nephrol. 33(8), 1569\u20131580 (2022). https:\/\/doi.org\/10.1681\/asn.2022020207","journal-title":"J. Am. Soc. Nephrol."},{"key":"4593_CR145","doi-asserted-by":"publisher","unstructured":"H. Wu, H. He, T. Han, X. Tian, Z. Zhu, Targeting cholesterol-dependent adrenal steroidogenesis for management of primary aldosteronism. Trends Endocrinol. Metab. (2025). https:\/\/doi.org\/10.1016\/j.tem.2024.12.001","DOI":"10.1016\/j.tem.2024.12.001"},{"issue":"38","key":"4593_CR146","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"J.W. McEvoy","year":"2024","unstructured":"J.W. McEvoy, C.P. McCarthy, R.M. Bruno, S. Brouwers, M.D. Canavan, C. Ceconi et al., 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur. Heart J. 45(38), 3912\u20134018 (2024). https:\/\/doi.org\/10.1093\/eurheartj\/ehae178","journal-title":"Eur. Heart J."},{"issue":"4","key":"4593_CR147","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1161\/hypertensionaha.120.16440","volume":"77","author":"C. Adolf","year":"2021","unstructured":"C. Adolf, V. G\u00f6rge, D.A. Heinrich, E. Hoster, H. Schneider, L. Handgriff et al., Altered Taste Perception for Sodium Chloride in Patients With Primary Aldosteronism: A Prospective Cohort Study. Hypertension. 77(4), 1332\u20131340 (2021). https:\/\/doi.org\/10.1161\/hypertensionaha.120.16440","journal-title":"Hypertension"},{"key":"4593_CR148","doi-asserted-by":"publisher","unstructured":"D. Pop, A. D\u0103d\u00e2rlat-Pop, R. Tomoaia, D. Zdrenghea, B. Caloian, Updates on the Renin-Angiotensin-Aldosterone System and the Cardiovascular Continuum. Biomedicines. 12(7) (2024). https:\/\/doi.org\/10.3390\/biomedicines12071582","DOI":"10.3390\/biomedicines12071582"},{"key":"4593_CR149","doi-asserted-by":"publisher","unstructured":"Y. Hu, J. Zhang, W. Liu, X. Su, Determining the Prevalence of Primary Aldosteronism in Patients With New-Onset Type 2 Diabetes and Hypertension. J Clin Endocrinol Metab. 2020;105(4). https:\/\/doi.org\/10.1210\/clinem\/dgz293","DOI":"10.1210\/clinem\/dgz293"},{"issue":"2","key":"4593_CR150","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s12020-024-03773-9","volume":"85","author":"M. Araujo-Castro","year":"2024","unstructured":"M. Araujo-Castro, J.G. Ruiz-S\u00e1nchez, P.P. Ram\u00edrez, P. Mart\u00edn, A. Rojas-Marcos, J.F. Aguilera-Saborido, G\u00f3mez, Cerezo et al., Practical consensus for the treatment and follow-up of primary aldosteronism: a multidisciplinary consensus document. Endocrine. 85(2), 532\u2013544 (2024). https:\/\/doi.org\/10.1007\/s12020-024-03773-9","journal-title":"Endocrine"},{"issue":"5","key":"4593_CR151","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"J.W. Funder","year":"2016","unstructured":"J.W. Funder, R.M. Carey, F. Mantero, M.H. Murad, M. Reincke, H. Shibata et al., The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 101(5), 1889\u20131916 (2016). https:\/\/doi.org\/10.1210\/jc.2015-4061","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"4593_CR152","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ando.2016.05.001","volume":"77","author":"L. Amar","year":"2016","unstructured":"L. Amar, J.P. Baguet, S. Bardet, P. Chaffanjon, B. Chamontin, C. Douillard et al., SFE\/SFHTA\/AFCE primary aldosteronism consensus: Introduction and handbook. Ann. Endocrinol. (Paris). 77(3), 179\u2013186 (2016). https:\/\/doi.org\/10.1016\/j.ando.2016.05.001","journal-title":"Ann. Endocrinol. (Paris)"},{"issue":"6","key":"4593_CR153","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/hyp.0000000000000066","volume":"71","author":"P.K. Whelton Jr.","year":"2018","unstructured":"P.K. Whelton, R.M. Carey, W.S. Aronow, D.E. Jr. Casey, K.J. Collins, C. Dennison Himmelfarb, ACC\/AHA\/AAPA\/ABC\/, \/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 71(6), 1269\u20131324 (2018). https:\/\/doi.org\/10.1161\/hyp.0000000000000066","journal-title":"Hypertension"},{"issue":"10","key":"4593_CR154","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/hjh.0000000000002510","volume":"38","author":"P. Mulatero","year":"2020","unstructured":"P. Mulatero, S. Monticone, J. Deinum, L. Amar, A. Prejbisz, M.C. Zennaro et al., Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J. Hypertens. 38(10), 1919\u20131928 (2020). https:\/\/doi.org\/10.1097\/hjh.0000000000002510","journal-title":"J. Hypertens."},{"key":"4593_CR155","doi-asserted-by":"publisher","unstructured":"W.C. Huang, F.H. Liu, H.M. Cheng, Y.C. Tsai, Y.T. Huang, T.S. Lai et al., Who needs to be screened for primary aldosteronism? J Formos Med Assoc. 2024;123 Suppl 2:S82-s90. https:\/\/doi.org\/10.1016\/j.jfma.2023.08.021","DOI":"10.1016\/j.jfma.2023.08.021"},{"issue":"6","key":"4593_CR156","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3803\/EnM.2023.1789","volume":"38","author":"J. Ha","year":"2023","unstructured":"J. Ha, J.H. Park, K.J. Kim, J.H. Kim, K.Y. Jung, J. Lee et al., 2023 Korean Endocrine Society Consensus Guidelines for the Diagnosis and Management of Primary Aldosteronism. Endocrinol. Metab. (Seoul). 38(6), 597\u2013618 (2023). https:\/\/doi.org\/10.3803\/EnM.2023.1789","journal-title":"Endocrinol. Metab. (Seoul)"},{"issue":"1","key":"4593_CR157","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12020-024-03751-1","volume":"85","author":"M. Araujo-Castro","year":"2024","unstructured":"M. Araujo-Castro, J.G. Ruiz-S\u00e1nchez, P. Parra Ram\u00edrez, P. Mart\u00edn, A. Rojas-Marcos, J.F. Aguilera-Saborido, G\u00f3mez, Cerezo et al., Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism. Endocrine. 85(1), 99\u2013121 (2024). https:\/\/doi.org\/10.1007\/s12020-024-03751-1","journal-title":"Endocrine"},{"key":"4593_CR158","doi-asserted-by":"publisher","unstructured":"S. Jiang, H. Li, L. Zhang, W. Mu, Y. Zhang, T. Chen et al., Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res. 53(D1):D1670-d6. 2025; https:\/\/doi.org\/10.1093\/nar\/gkae973","DOI":"10.1093\/nar\/gkae973"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04593-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04593-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04593-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:12:29Z","timestamp":1775095949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04593-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":158,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4593"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04593-9","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"128"}}